Stock Fundamentals

IPCA Labs: Buy

Srividhya Sivakumar | Updated on March 12, 2018 Published on January 14, 2012

IPCAcol.eps

Growing presence in the export and domestic markets is an healthy indicator.



Growing presence in the export and domestic markets, expected improvement in the productivity of its sales force and manageable debt on its books make the stock of IPCA Laboratories a good long-term investment bet. At the current market price of Rs 274, the stock trades at about 10 times its likely FY13 per share earnings. This is at a discount to its peers, and leaves sufficient room for the stock price to appreciate in the long term. That the company doesn't have any ongoing altercation with the regulator over its existing manufacturing facilities (unlike some of its peers) puts it at an advantage, what with the export potential opening up in developed markets.

Exports thrust

Given IPCA's established presence in most export markets — it exports to more than 110 countries and is among the top 10 pharma exporters from India — it stands to benefit immensely from the growing demand for generics across the globe. Presently, it has filed 24 Abbreviated New Drug Applications (ANDAs) with US FDA, of which 12 ANDAs have been approved. Further, it has filed 60 Drug Master Files (DMFs) with the FDA for Active Pharmaceutical Ingredients (APls).

The approval of its Indore facility by the US FDA would provide the much-needed additional thrust, as IPCA can then launch more products. An approval can see the launch of five ANDAs in the US. Note that the management expects the revenue from this facility (once fully operational) to peak at about Rs 300-400 crore.

That said, there still is no clear timeline on when the approval can be expected — the FDA has still not scheduled any inspection dates. The management expects it to be in place in the coming three months. But, till such time, the new facility would be a drag on margins given its recurring cost of maintenance. Expected growth in anti-malarial business, tender business in Africa and launches in the branded formulation space in other countries too would help.

Notably, exports make up more than half its revenues (56 per cent of Apr-Sep 2011) and have clocked a compounded growth rate of 24 per cent over the last three years. The export thrust helped IPCA expand its operating margins in the Apr-Sep 2011 period by 174 basis points to 22 per cent. The growth momentum is expected to continue in the coming years, given the many potential upside catalysts.

Domestic business

While IPCA's domestic formulation business has managed decent long-term growth — 17 per cent CAGR over the last three years — its performance in the first half of FY12 has been relatively muted. In the six-month period, its Indian formulation business grew only by six per cent to Rs 509 crore, driven by lower sales in anti-malarial and anti-infectives (in line with industry trend) and high attrition.

But, in November, the company saw a strong bounce back in anti-infectives; this may reflect positively on its December quarter performance. Improved focus on the high-margin pain and CVS segments, given that anti-malarials and anti-infectives typically see pricing pressures too, would help it in the long run. With the company having nearly doubled its sales force to 400 in the last two years, the coming years could also see the benefit of improved productivity kick in.

Even the proposed drug pricing policy would have little impact on its revenues. Though 67 per cent of its products would come under the proposed price control, the impact would be minimal (2-3 per cent) as only a couple of IPCA's products are brand leaders in their respective therapies.

Guidance

The management expects to end FY12 with a 20 per cent revenue growth, driven largely by exports. It expects only a 9-10 per cent growth in domestic business in the second half of the current fiscal. For FY13, it expects a 16-18 per cent growth led by new launches. While it looks achievable, timely regulatory approval of its Indore facility will hold the key.

Published on January 14, 2012

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
null
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.